|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 12 (June 15), 2000:
pp. 3891-3899
TEL-JAK2 transgenic mice develop T-cell leukemia
Clémence Carron,
Françoise Cormier,
Anne Janin,
Virginie Lacronique,
Marco Giovannini,
Marie-Thérèse Daniel,
Olivier Bernard, and
Jacques Ghysdael
From the Centre National de la Recherche Scientifique (CNRS) UMR
146-Institut Curie, Centre Universitaire, Orsay, France; Service
Central d'Anatomie et de Cytologie Pathologiques and INSERM U462
Laboratoire Central d'Hématologie, Hopital St. Louis, Paris,
France; and INSERM U434-CEPH, Paris, France.
We previously reported a fusion between TEL and JAK2
in a t(9;12)(p24;p13) chromosomal translocation in childhood acute
T-cell leukemia. This fusion gene encodes a TEL-JAK2 chimeric protein in which the 336 amino-terminal residues of TEL, including its specific
self-association domain, are fused to the kinase domain of JAK2.
TEL-JAK2 exhibits constitutive activation of its tyrosine kinase
activity which, in turn, confers growth factor-independent proliferation to the interleukin-3-dependent Ba/F3 hematopoietic cell
line. To elucidate the properties of TEL-JAK2 in primary cells and to
create an animal model for TEL-JAK2-induced leukemia, we generated
transgenic mice in which the TEL-JAK2 complementary DNA was placed
under the transcriptional control of the EµSR enhancer/promoter.
TEL-JAK2 founder mice and their transgenic progeny developed fatal
leukemia at 4 to 22 weeks of age. Selective amplification of
CD8-positive T cells was observed in blood, lymph nodes, thymus,
spleen, and bone marrow. Expression of a tyrosine-phosphorylated TEL-JAK2 protein and activation of STAT1 and STAT5 (signal transducer and activator of transcription) were detected in leukemic tissues. TEL-JAK2 diseased mice also displayed invasion of nonhematopoietic organs, including liver, brain, lung, and kidney, by leukemic T cells.
Leukemic organs of founder and transgenic progeny contained a
monoclonal/oligoclonal T-cell population as analyzed by the rearrangement of the TCR locus. Transplantation of TEL-JAK2 leukemic cells in nude mice confirmed their invasive nature. We conclude that
the TEL-JAK2 fusion is an oncogene in vivo and that its
expression in lymphoid cells results in the preferential expansion of
CD8-positive T cells.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Bessette, M. L. Lang, R. A. Fava, M. Grundy, J. Heinen, L. Horne, R. Spolski, A. Al-Shami, H. C. Morse III, W. J. Leonard, et al.
A Stat5b transgene is capable of inducing CD8+ lymphoblastic lymphoma in the absence of normal TCR/MHC signaling
Blood,
January 1, 2008;
111(1):
344 - 350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. R. dos Santos, D. S. Rickman, A. de Reynies, F. Cormier, M. Williame, C. Blanchard, M.-H. Stern, and J. Ghysdael
Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia
Blood,
May 1, 2007;
109(9):
3972 - 3981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dumortier, R. Jeannet, P. Kirstetter, E. Kleinmann, M. Sellars, N. R. dos Santos, C. Thibault, J. Barths, J. Ghysdael, J. A. Punt, et al.
Notch Activation Is an Early and Critical Event during T-Cell Leukemogenesis in Ikaros-Deficient Mice
Mol. Cell. Biol.,
January 1, 2006;
26(1):
209 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Maeda, F. Yagasaki, M. Ishikawa, N. Takahashi, and M. Bessho
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML
Blood,
March 1, 2005;
105(5):
2115 - 2123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Barata, V. A. Boussiotis, J. A. Yunes, A. A. Ferrando, L. A. Moreau, J. P. Veiga, S. E. Sallan, A. T. Look, L. M. Nadler, and A. A. Cardoso
IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL
Blood,
March 1, 2004;
103(5):
1891 - 1900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Benekli, M. R. Baer, H. Baumann, and M. Wetzler
Signal transducer and activator of transcription proteins in leukemias
Blood,
April 15, 2003;
101(8):
2940 - 2954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Frantsve, J. Schwaller, D. W. Sternberg, J. Kutok, and D. G. Gilliland
Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation
Mol. Cell. Biol.,
May 15, 2001;
21(10):
3547 - 3557.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. Chen, J. M. Lee, Y. Zong, M. Borowitz, M. H. Ng, R. F. Ambinder, and S. D. Hayward
Linkage between STAT Regulation and Epstein-Barr Virus Gene Expression in Tumors
J. Virol.,
March 15, 2001;
75(6):
2929 - 2937.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
X. Zhang, R. Subrahmanyam, R. Wong, A. W. Gross, and R. Ren
The NH2-Terminal Coiled-Coil Domain and Tyrosine 177 Play Important Roles in Induction of a Myeloproliferative Disease in Mice by Bcr-Abl
Mol. Cell. Biol.,
February 1, 2001;
21(3):
840 - 853.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Buijs, L. van Rompaey, A. C. Molijn, J. N. Davis, A. C. O. Vertegaal, M. D. Potter, C. Adams, S. van Baal, E. C. Zwarthoff, M. F. Roussel, et al.
The MN1-TEL Fusion Protein, Encoded by the Translocation (12;22)(p13;q11) in Myeloid Leukemia, Is a Transcription Factor with Transforming Activity
Mol. Cell. Biol.,
December 15, 2000;
20(24):
9281 - 9293.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. H.-H. Nguyen, J. M.-Y. Ho, B. K. Beattie, and D. L. Barber
TEL-JAK2 Mediates Constitutive Activation of the Phosphatidylinositol 3'-Kinase/Protein Kinase B Signaling Pathway
J. Biol. Chem.,
August 24, 2001;
276(35):
32704 - 32713.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
